ArticleNeuro-oncology advances

Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.

Pablo Cerezuela-Fuentes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.